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Liver Transplantation

Center-driven and Clinically Driven Variation
in US Liver Transplant Maintenance
Immunosuppression Therapy: A National
Practice Patterns Analysis
Mustafa Nazzal, MD,1 Krista L. Lentine, MD, PhD,1 Abhijit S. Naik, MD, MPH,2 Rosemary Ouseph, PhD,1
Mark A. Schnitzler, PhD,1 Zidong Zhang, MPH,1 Henry Randall, MD,1 Vikas R. Dharnidharka, MD, MPH,3
Dorry L. Segev, MD, PhD,4 Bertram L. Kasiske, MD,5 Gregory P. Hess, MD, MSc,6 Tarek Alhamad, MD, MSc,7
Mara McAdams-Demarco, PhD,4 and David A. Axelrod, MD, MBA8

Background. Variation in the use of immunosuppression regimens after liver transplant has not been well described.
Methods. Immunosuppression regimens used after liver transplant were identified in a novel database integrating national

transplant registry and pharmacy fill records for 24 238 recipients (2006-2014). Bilevel hierarchical models were developed
to quantify the effects of transplant program, recipient, and donor characteristics on regimen choice. Results. In the first
6 months after transplant, triple immunosuppression (tacrolimus, antimetabolite, corticosteroids) was the most common regimen
(42.9%). By months 7 to 12, immunosuppression regimens were more commonly antimetabolite sparing (33.7%) or steroid sparing (26.9%), followed by triple (14.4%), mammalian target of rapamycin inhibitor (mTORi)-based (12.1%), or cyclosporine-based
(9.2%). Based on intraclass correlation analysis, clinical characteristics explained less than 10% of the variation in immunosuppression choice, whereas program preference/practice explained 23% of steroid sparing, 26% of antimetabolite sparing, 28%
of mTORi, and 21% of cyclosporine-based regimen use. Although case factors were not dominant practice drivers, triple immunosuppression in months 7 to 12 was more common among retransplant recipients and those with prior acute rejection. Hepatocellular carcinoma as cause of liver failure (adjusted odds ratio [aOR], 2.15; P<0.001), cancer within 6 months (aOR, 6.07;
P<0.001), and 6-month estimated glomerular filtration rate less than 30 mL/min per 1.3 m2 (aOR, 1.98; P<0.001) were associated
with mTORi use compared with triple immunosuppression in months 7 to 12, whereas acute rejection predicted lower use (aOR,
0.72; P=0.003). Conclusions. Liver transplant immunosuppression is dominantly driven by program preference, but case factors also affect regimen choice. This variation frames a natural experiment for future evaluations of comparative efficacy.
(Transplantation Direct 2018;4: e364; doi: 10.1097/TXD.0000000000000800. Published online 13 June, 2018.)
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iver transplant recipients have traditionally required
lower levels of immunosuppression (ISx) than other solid
organ transplant recipients. However, inadequate ISx coverage
can result in acute rejection (AR) and graft loss, whereas
overuse contributes to chronic renal insufficiency, malignancy, and infection.1 A recent Cochrane review of induction
and maintenance ISx in liver transplantation concluded that
published data were insufficient to identify an optimal ISx,
and called for novel strategies to assess variation in ISxrelated outcomes.2 The development of novel “big data”
linking administrative and clinical data sets offers the potential
to assess outcome variation by ISx regimen while controlling
for marked differences in patient and donor characteristics
which characterize contemporary liver transplant practice.
Calcineurin inhibitor (CNI)-based regimens including
tacrolimus (Tac) or cyclosporine (CsA) remain the foundation of postliver transplant maintenance ISx. Calcineurin
inhibitor–based ISx results in low rates of AR and prolonged
graft survival, and Tac is associated with better outcomes
than CsA in head-to-head comparison.3 However, in subpopulations, alternative regimens may be superior, because
Tac has been associated with an increase in de novo malignancies,
a 40% increased risk of posttransplant diabetes, and more aggressive recurrence of autoimmune disease.4 In addition, CNIs
contribute to the development of chronic kidney disease (glomerular filtration rate [GFR] <30 mL/min per 1.73 m2) in nearly
20% of liver transplant recipients at 5 years.5 Strategies to decrease the nephrotoxicity associated with CNIs include the
use of induction therapy to delay CNI introduction and conversion to mammalian target of rapamycin inhibitor (mTORi)
maintenance to allow lower CNI therapeutic levels or avoid
CNIs altogether.6,7 Unfortunately, mTORis have been associated
with hepatic artery thrombosis and increased AR rates, which
could mitigate the advantages of mTORi on kidney function.8,9
Patients with hepatocellular cancer (HCC) represent a
growing proportion of liver transplant recipients who may
benefit from a tailored ISx strategy. Hepatocellular cancer
recurrence is believed to be influenced by degree of ISx, is
difficult to treat, and leads to high mortality.10 The mTORibased regimens may have some antineoplastic benefits for
patients with HCC.11 Although the use of sirolimus (SRL) is particularly challenging early posttransplant due to risk of vascular
complications and poor wound healing, selected trials have suggested benefit if therapy is delayed for at least 30 days.8,9
The evaluation of customized ISx strategies in liver transplantation has thus far been limited to trends in ISx use after
liver transplant have been reported using national registry
data at time of discharge.2,12 To characterize contemporary
practices in liver transplant ISx, we examined a novel database integrating national registry and pharmacy fill records
for a national, contemporary sample of US liver transplant
recipients using a multilevel analytic framework in the early
(0-6 months) and later (7-12 months) posttransplant periods
as distinguish between clinically driven differences in ISx regimen and those based simply on established practice.
MATERIALS AND METHODS
Data Sources

We conducted a retrospective cohort study using linked
healthcare databases in the US to ascertain patient characteristics, pharmacy fill records, and outcome events for liver
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transplant recipients. This study used transplant data from
the Scientific Registry of Transplant Recipients (SRTR). The
SRTR system includes data on all donors, waitlisted candidates, and transplant recipients in the US, submitted by the
members of the Organ Procurement and Transplantation
Network (OPTN). The Health Resources and Services Administration, US Department of Health and Human Services,
provides oversight of the activities of the OPTN and SRTR
contractors. Baseline demographic information ascertained
for liver transplant recipients from OPTN included age, sex,
and race as reported by the transplant centers.
Pharmacy fill data were assembled by linking SRTR records for liver transplant recipients with billing claims from
Symphony Health (SH), a large US pharmaceutical claims
data warehouse that collects prescription drug fill records
including self-paid fills and those reimbursed by private
and public payers.13 Symphony Health comprises National
Council for Prescription Drug Program format prescription
claims aggregated from multiple sources including claims
warehouses, retail pharmacies, and prescription benefit managers for approximately 60% of US retail pharmacy transactions. Individual claim records include the pharmacy fill date
with the national drug code identifying agent and dosage. After institutional review board and Health Resources and Services Administration approvals, SH records were linked with
SRTR records for liver transplant recipients. We applied a deterministic deidentification strategy wherein patient identifiers (last name, first name, date of birth, sex, and ZIP code
of residence) were transformed before delivery to the Saint
Louis University researchers with Health Information Portability and Accountability Act and Health Information
Technology for Economic and Clinical Health (HITECH)certified encryption technology from SH. The patient
deidentification software employs multiple encryption algorithms in succession to guarantee that the resulting “token”
containing encrypted patient identifiers can never be
decrypted. However, the algorithm yields the same results
for a given set of data elements, such that linkages by
unique anonymous tokens are possible.
Sample and Clinical Characteristics

We identified adult liver transplant recipients (age, ≥18
years) with SRTR records of liver transplant in 2006 and
2014 and available pharmaceutical fill records over
12 months posttransplant. Recipient clinical and demographic characteristics, characteristics of the donated organ,
and other transplant factors including ischemic time and
sharing, were defined by the OPTN Transplant Candidate
and Recipient Registration forms (Table 1).
Immunosuppression

Using pharmacy fill records, ISx regimens were classified
into 6 mutually exclusive groups as per previous methods:
group 1 (reference), standard triple therapy, defined as Tac with
mycophenolic acid (MPA) (mycophenolate mofetil, mycophenolate sodium), or azathioprine (AZA), and prednisone
(Pred), “Tac+MPA/AZA+Pred”; group 2, corticosteroidsparing, “Tac+MPA/AZA”; group 3, MPA/AZA sparing,
“Tac alone, Tac+Pred”; group 4, mTORi-based, defined by
any fill for SRL as the mTORi available in the study period,
with or without other agents including CNI, “mTORibased”; group 5, CsA-based, defined by CsA without SRL,
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TABLE 1.

Recipient, donor, and transplant characteristics according to liver transplant maintenance ISx regimen, months 0 to
6 posttransplant
Tac + MPA/AZA+Pred
Sample size
Induction regimen
No induction
Thymoglobulin
IL-2 receptor antibody
Alemtuzumab
Other induction
Recipient characteristics
Age, y
18-30
31-45
46-60
>60
Male
Race
White
Black
Hispanic
Other
BMI, kg/m2
<18.5
18.5-24.9
25-30
>30
Unknown
Cause of liver failure
Hepatocellular carcinoma
Hepatitis C
Hepatitis B
Metabolic
Alcoholic
NASH
Other/Unknown
Comorbidities
Diabetes
Coronary artery disease/angina
COPD
Hypertension
Cerebral vascular diseases
Peripheral vascular diseases
Malignancy history
Laboratory MELD score
10-14
15-19
20-24
25-29
30-34
35-39
≥40
Primary insurance
Private
Public
Self/other

10 396

Tac + MPA/AZA

Tac alone, Tac + Pred

mTORi-based

CsA-based

Other

3736

4385

2447

2124

1150

a

a

a

a

a

81.7
3.0
14.6
0.1
0.6

59.9
19.6
17.5
0.5
2.5

67.3
14.6
12.7
2.5
2.9

66.2
12.2
19.5
0.5
1.6

68.2
9.2
20.4
0.4
1.7

74.0
8.5
16.1
0.4
1.0

a

b

a

a

b

5.0
12.7
54.1
28.2
59.2

3.2
11.5
61.2
24.1
59.1

4.6
11.5
57.3
26.6
59.9

2.3
8.2
56.0
33.5
59.2

3.1
9.2
59.6
28.1
58.7

5.2
11.7
58.4
24.8
59.0

a

c

c

76.5
9.4
10.0
4.2

75.9
7.1
13.0
4.1

71.3
11.5
13.0
4.3

c

73.8
8.2
12.1
5.9

73.6
10.0
11.7
4.7

73.9
8.9
12.1
5.1

1.8
29.4
33.1
34.2
1.6

2.1
27.4
34.0
34.8
1.9

2.2
28.2
35.2
32.5
1.9

1.4
27.2
35.5
34.2
1.8

2.0
28.3
35.2
33.3
1.2

2.4
27.0
34.8
34.0
1.8

a

a

a

a

a

21.2
23.2
1.8
2.5
13.4
7.9
30.0

25.4
30.6
1.9
1.9
12.5
7.3
20.5

23.9
27.6
1.9
2.4
12.6
6.3
25.3

30.5
24.6
1.7
2.3
11.7
8.5
20.8

17.6
36.0
1.9
2.3
13.8
7.4
21.1

22.1
28.5
1.7
2.2
9.9
5.7
29.9

0.2
1.8
1.7
20.3
0.8
0.9
19.2

0.3
2.6b
2.3b
20.9
0.5
1.1
20.3

0.3
2.7c
1.5
18.9
0.5b
0.8
23.0a

0.3
2.1
1.4
24.1a
0.7
0.7
23.2a

0.2
2.5b
2.4b
20.5
0.6
0.8
18.8

0.4
2.0
1.7
20.7
0.5
0.7
18.0

b

41.5
22.5
12.9
8.1
6.4
4.7
3.9

b

b

44.1
23.6
12.4
7.1
5.3
3.9
3.6

44.6
22.3
12.8
7.6
5.3
4.3
3.2

c

44.5
21.3
12.4
7.7
6.3
3.7
4.1

b

63.2
36.1
0.7

63.1
36.4
0.5

60.5
38.5
1.0

36.5
24.5
13.5
9.8
7.5
4.2
4.0

43.4
21.4
14.0
8.4
5.8
3.6
3.5

c

62.7
36.4
0.9

59.0
40.2
0.9

61.7
37.4
0.9

Continued next page
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TABLE 1. (Continued)
Tac + MPA/AZA+Pred
Previous transplant
eGFR at discharge, ml/min per 1.73 m2
≥ 90
60-89
30-59
≤ 29
Unknown
Function status at transplant
Severe impairment
Moderate impairment
Mild impairment
Unknown
Donor factors
Donor Risk Index score
0 to <1.5
1.5 to <2.0
2.0 to <2.5
≥ 2.5
Living donor
Transplant year
2006-2009
2010-2012
2013-2014

8.2
33.1
23.5
20.5
7.9
15.0
32.4
24.7
41.0
1.9

Tac + MPA/AZA
7.2b

Tac alone, Tac + Pred

6.8b

a

34.3
23.3
20.9
7.7
13.9

38.9
24.8
19.2
6.5
10.6

b

b

30.4
25.3
43.1
1.3

31.5
23.6
43.5
1.4

c

33.0
34.3
19.7
8.5
4.5
9.3
44.0
46.7

mTORi-based

9.5

CsA-based

Other

11.2a

11.8a

a

c

b

25.8
22.8
26.0
11.8
13.7

29.6
25.6
23.1
9.1
12.7

31.7
26.2
23.0
7.0
12.2

a

33.6
22.9
41.4
2.2

38.9
25.3
34.4
1.5

31.0
25.7
41.1
2.1

a

b

b

34.3
36.4
19.0
6.9
3.5

34.5
35.0
18.7
7.7
4.1

37.6
35.4
18.1
6.5
2.5

34.5
36.8
18.3
6.6
3.8

36.8
34.8
17.1
7.1
4.2

a

a

b

a

a

12.6
45.8
41.6

16.4
48.1
35.5

10.9
41.3
47.8

12.0
53.6
34.4

17.1
53.3
29.6

P values for difference in distribution of case factors according to ISx regimen: aP < 0.0001; b 0.02 ≤ P < 0.05; c0.0001 ≤ P < 0.01.
AZA, azathioprine; BMI, body mass index; COPD, chronic obstructive pulmonary disease; CsA, cyclosporine; eGFR, estimated glomerular filtration rate; MPA, mycophenolic acid; MELD, Model for End-Stage Liver
Disease; NASH, nonalcoholic steatohepatitis; Pred, prednisone; Tac, tacrolimus; mTORi, mammalian target of rapamycin inhibitor.

“CsA-based”; group 6, “other regimens” including CsA
withdrawal, or other trial medications.13 Patients in groups
1 to 3 did not receive SRL or CsA.
Analyses

Observed Variation in Regimen Use Across Centers
To visually assess unadjusted variation in maintenance ISx
use at the center level across the United States, the observed
proportion of patients receiving each induction regimen was
computed for each center and displayed as stacked bar plots.
Combined Center and Case-level Modeling
Bilevel hierarchical models were constructed to adjust for
clustering effects. Level 1 comprised patient/donor and transplant (clinical) factors, and level 2 represented the center,
wherein use of each alternative regimen was compared individually to the reference regimen (pairwise). Empirical Bayes
estimates (EBE) provided the adjusted proportion (with 95%
confidence intervals [CI]) of use of a regimen of interest compared with the reference regimen, incorporating case-mix adjustment from the hierarchical model. A 95% CI for a given
center's EBE of use of a regimen of interest that did not include the median national rate of use indicated a prescribing
pattern statistically significantly different from the expected
rate of use for that regimen.
Heterogeneity in ISx prescribing across centers was quantified using intraclass correlation (ICC) and median odds ratios
(MOR). The ICC is defined as the ratio of cluster variance
(center impact) to the total observed variance in ISx use,
with contributions in our study framework defined as

center-related, clinically related, and other unmeasured effects. In this context, the ICC quantifies the proportion of total variance in ISx use that is accounted for by center. The
MOR provides the median of the odds that patients with
identical characteristics will receive the ISx regimen of interest when 2 centers are drawn at random (performed for all
possible pairs of centers). For example, a MOR of 2.0 means
that if centers are selected at random across all centers, a patient with a given set of characteristics is, on an average, twice
as likely to receive the ISx regimen of interest at one of the
randomly selected centers as at the other.14 The adjusted
odd ratio (95% LCL aOR95% UCL) of receiving a maintenance
regimen other than the triple-therapy reference was determined for patient and donor factors, after accounting for
the effect of center using the hierarchical model.
Data were analyzed using Stata 13, College Station, TX.
Hierarchical logistic regression modeling was in Stata using
the “xtmelogit” command with center as a random intercept.
The ICC and the MOR were calculated using “xtmrho” (thirdparty suite) command.

Contributions of Case-level Factors to Variation in
ISx Use
To quantify the degree of variance in ISx regimen use explained by recipient and donor characteristics, we performed
multivariate logistic regression modeling with maintenance
regimen as the dependent variable and case factors as the predictors. Pairwise models were constructed to assess the relative likelihood of using each specific regimen (as outlined
above) compared with triple ISx.

© 2018 Wolters Kluwer
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Regimen Change Analysis
We examined the frequencies of liver transplant recipients
who remained on the same regimen after the 0- to 6-month
posttransplant period and those who switched to new regimens in the 7- to 12-month period. To examine the correlates
of change in ISx, we performed multivariate logistic regression
modeling adjusted for recipient, donor, and transplant risk factors with “change in ISx regimen” as the dependent variable.
RESULTS
Between 2006 and 2014, 24 238 liver transplants were
performed in the US; 51 011 linked pharmacy fill records
were available. In the first 6 months after transplant, a plurality (42.9%) of transplant recipients received triple therapy;
18.1% received MPA/AZA-sparing (Tac alone, Tac+Pred),
15.4 steroid-sparing, 10.1% mTORi-based, and 8.8% CsAbased. Most patients in the mTORi-based group also received CNI (Tac, 72.5%; CsA, 12.4%). Induction therapy
at liver transplant varied with maintenance ISx regimen
(Table 1). Patients receiving triple ISx therapy were unlikely
to receive induction (81.7% did not), and those who did
most frequently received IL-2 receptor blocking antibodies
(IL2rAb, 14.6%). Conversely, induction was used in 40.1%
of patients on steroid-free regimens (TMG, 19.6%; IL2rAb,
17.5%) and in 32.7% of patients managed with MPA
avoidance (TMG, 14.6%; IL2rAb, 12.7%).
By 7 to 12 months after transplant, the pattern of ISx
shifted (Table 2; Figure S1, SDC, http://links.lww.com/
TXD/A103). Only 14.4% of patients remained on triple
therapy. Mycophenolic acid sparing regimens were the most
common (33.7%), followed by steroid-sparing (26.9%).
mTORi-based ISx was used in 12.1% and CsA-based in
9.2%. Only 27.0% of patients on triple therapy in the first
6 months remained, so at 6 to 12 months, 34.0% were
changed to steroid-sparing and 31.0% to MPA/AZA-sparing
regimens. In contrast, most patients on MPA/AZA-sparing
(82.0%), mTORi-based (79.3%), and CsA-based (80.6%)
ISx remained on their initial regimen.
Patient Characteristics and ISx Regimen Use

Some patient characteristics were associated with maintenance ISx regimens at 0 to 6 months posttransplant (Table 3).
Younger patients (ages, 19-30 years) were less likely than
patients aged 31 to 45 years to receive steroid sparing versus
triple therapy (aOR 0.50 0.670.90). Older patients (age >45 years)

5

were more likely to receive MPA/AZA-sparing, mTORi-based,
or CsA-based regimens than to receive triple therapy
(P<0.05 for all). Black patients were less likely to receive
CsA-based regimens (aOR 0.590.720.89) and Hispanics were less
likely to receive mTORi-based regimens (aOR 0.620.740.88)
versus triple therapy. Recipients with low body mass index
(BMI) were more frequently given steroid-sparing and MPA/
AZA-sparing regimens. Compared with recipients with
alcoholic liver failure, those with HCC were 81% more
likely to receive mTORi-based regimens (aOR 1.48 1.812.21)
than triple therapy. Diabetic patients were more commonly
given MPA/AZA-sparing regimens than triple therapy
(aOR 1.112.445.39). The lower the estimated GFR (eGFR),
the higher the odds of receiving mTORi-based ISx (eGFR,
60-89: aOR 1.091.271.47; eGFR 30-59: aOR 1.381.601.86;
eGFR 0-29 ml/min/1.73 m2: aOR 1.732.112.58). Over time, use
of triple therapy was more likely compared with the other
ISx regimens, shown by aOR <1 for all nontriple therapy
regimens in 2010 to 2012 versus 2006 to 2009.
Associations of many case factors with ISx in months 7 to
12 were similar to those in the first 6 months (Table S1, http://
links.lww.com/TXD/A106). However, at 7 to 12 months, recipients with BMI >30 kg/m2 were significantly more likely to
receive a steroid-sparing regimen (aOR 1.101.161.33). Recipients with AR within the first 6 months were more likely to receive triple therapy in the later period. In addition, recipients
with incident malignancy in first 6 months were 6 times more
likely (aOR 3.266.0711.27) to receive an mTORi-based regimen than to receive triple therapy. Among patients with severely impaired functional status, CsA-based regimens were
more likely to be used (1.251.96 3.09).
Donor Characteristics and ISx Regimen Choice

Recipients of high Donor Risk Index score (≥2.5)
(aOR 0.63 0.79 0.99) or living donor (aOR 0.460.630.88) allografts were less likely to receive mTORi-based regimens
than to receive triple therapy (Table 3). Recipients who
had undergone previous transplant were more commonly
given MPA/AZA-sparing (aOR 1.211.411.64), CsA-based
(aOR 1.261.501.79), or other ISx maintenance (aOR 1.14
1.421.77) versus triple therapy.
Center Variation in ISx Use

Choice of ISx regimens differed substantially across centers
in the first 6 months after transplant (Figure 1). Regimen use
by center varied from 0% to 94.4% for triple therapy, 0%

TABLE 2.

ISx in months 7 to 12 compared with initial regimen months 0 to 6 posttransplant
% of Patients on indicated regimen in months 7-12
Regimen months 7-12

Tac + MPA/AZA + Pred
14.4

Regimen months 0-6
Tac+MPA/AZA + Pred, %
Tac+MPA/AZA, %
Tac alone, Tac+Pred, %
mTORi-based, %
CsA-based, %
Other, %

27.0
5.2
4.5
2.4
3.4
10.6

Tac+MPA/AZA

Tac alone, Tac+ Pred

mTORi-based

CsA-based

26.9
33.7
12.1
Patients on indicated regimen in months 6-12 who received reach regimen in months 7-12
34.0
31.0
3.4
56.9
29.3
3.7
6.9
82.0
3.7
4.6
7.6
79.3
3.2
4.2
5.6
25.7
15.4%
7.5%

Other

9.2

3.7

1.5
1.5
1.8
4.3
80.6
5.6

3.2
3.5
1.1
1.7
3.0
35.1
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TABLE 3.

Associations of recipient, donor, and transplant case characteristics with liver transplant maintenance ISx regimen use
in months 0 to 6 posttransplant compared with triple therapy (reference regimen)

Induction regimen
No induction
Thymoglobulin
IL-2 receptor antibody
Alemtuzumab
Other induction
Recipient characteristics
Age, y
18-30
31-45
46-60
>60
Male
Race
White
Black
Hispanic
Other
BMI, kg/m2
<18.5
18.5-24.9
25-30
>30
Unknown
Cause of liver failure
Hepatocellular carcinoma
Hepatitis C
Hepatitis B
Metabolic
Alcoholic
NASH
Other
Comorbidities
Diabetes
Coronary artery disease/angina
COPD
Hypertension
Cerebral vascular disease
Peripheral vascular disease
Malignancy history
Laboratory MELD score
10-14
15-19
20-24
25-29
30-34
35-39
≥40
Primary insurance
Private
Public
Self/other

Tac + MPA/AZA

Tac alone, Tac + Pred

mTORi-based

CsA-based

Other

0.74 (0.63-0.86)a
1.30 (1.01-1.67)b
Reference
0.69 (0.28-1.69)
0.97 (0.62-1.53)

1.00 (0.86-1.16)
1.58 (1.23,2.04)a
Reference
1.47 (0.69-3.14)
1.28 (0.82-2.01)

0.67 (0.57-0.78)a
1.08 (0.81-1.44)
Reference
0.93 (0.38-2.29)
1.10 (0.63-1.94)

0.97 (0.83-1.14)
1.05 (0.78-1.42)
Reference
0.75 (0.29-1.95)
1.08 (0.63-1.88)

0.86 (0.69-1.07)
1.00 (0.68-1.48)
Reference
0.73 (0.21-2.50)
0.96 (0.45-2.06)

0.67 (0.50-0.90)b
Reference
1.08 (0.92-1.27)
0.99 (0.83-1.19)
1.01 (0.92-1.12)

0.93 (0.73-1.18)
Reference
1.22 (1.05-1.41)b
1.27 (1.08-1.49)b
1.04 (0.95-1.14)

0.71 (0.49-1.01)
Reference
1.41 (1.16-1.71)a
1.64 (1.34-2.02)a
1.01 (0.90-1.12)

0.98 (0.70-1.36)
Reference
1.35 (1.12-1.63)c
1.65 (1.34-2.02)a
0.98 (0.88-1.09)

0.92 (0.64-1.32)
Reference
1.07 (0.86-1.35)
1.04 (0.80-1.33)
1.00 (0.86-1.15)

Reference
0.93 (0.78-1.10)
0.93 (0.79-1.09)
0.95 (0.76-1.20)

Reference
0.93 (0.79-1.09)
0.97 (0.83-1.12)
0.97 (0.78-1.20)

Reference
0.87 (0.72-1.05)
0.74 (0.62-0.88)c
0.76 (0.59-0.98)b

Reference
0.72 (0.59-0.89)c
1.04 (0.88-1.23)
0.74 (0.57-0.97)b

Reference
1.08 (0.86-1.36)
1.05 (0.84-1.31)
0.83 (0.59-1.17)

1.53 (1.08-2.15)b
Reference
1.09 (0.97-1.24)
1.10 (0.97-1.24)
1.83 (1.24-2.70)c

1.37 (1.00-1.89)
Reference
1.12 (1.00-1.25)b
1.07 (0.95-1.20)
1.04 (0.72-1.49)

1.16 (0.75-1.77)
Reference
1.03 (0.90-1.17)
0.92 (0.80-1.05)
1.07 (0.69-1.64)

1.36 (0.93-2.00)
Reference
1.05 (0.92-1.20)
0.95 (0.83-1.09)
1.02 (0.61-1.71)

1.42 (0.89-2.28)
Reference
1.18 (0.99-1.40)
1.15 (0.96-1.38)
0.98 (0.57-1.68)

1.38 (1.15-1.67)c
1.53 (1.30-1.81)a
1.00 (0.68-1.47)
0.87 (0.61-1.24)
Reference
1.00 (0.80-1.24)
0.64 (0.54-0.76)a

1.23 (1.03-1.45)b
1.22 (1.05-1.42)b
1.11 (0.78-1.58)
1.07 (0.79-1.45)
Reference
0.81 (0.66-1.00)
0.79 (0.68-0.92)b

1.81 (1.48-2.21)a
1.19 (0.99-1.43)
1.26 (0.84-1.91)
1.11 (0.77-1.60)
Reference
1.09 (0.87-1.38)
0.79 (0.65-0.95)b

0.96 (0.78-1.17)
1.50 (1.26-1.78)a
1.15 (0.76-1.72)
0.87 (0.60-1.26)
Reference
0.91 (0.72-1.16)
0.64 (0.53-0.77)a

1.52 (1.15-2.01)b
1.59 (1.24-2.05)a
1.17 (0.66-2.08)
1.27 (0.77-2.07)
Reference
0.94 (0.66-1.33)
1.16 (0.90-1.49)

1.46 (0.57-3.76)
1.25 (0.90-1.74)
1.32 (0.95-1.85)
0.99 (0.88-1.12)
0.70 (0.38-1.31)
1.33 (0.84-2.10)
0.99 (0.87-1.12)

2.44 (1.11-5.39)b
1.01 (0.74-1.40)
0.82 (0.58-1.17)
0.90 (0.80-1.01)
0.64 (0.35-1.18)
0.60 (0.35-1.01)
1.15 (1.02-1.29)

1.66 (0.59-4.65)
0.94 (0.65-1.36)
0.82 (0.55-1.23)
1.05 (0.93-1.20)
1.07 (0.59-1.93)
0.75 (0.42-1.33)
1.29 (1.13-1.47)a

1.01 (0.34-2.98)
1.18 (0.82-1.69)
1.21 (0.84-1.74)
0.98 (0.86-1.12)
0.72 (0.37-1.43)
0.81 (0.46-1.43)
1.02 (0.88-1.17)

1.29 (0.39-4.25)
1.01 (0.62-1.65)
1.11 (0.66-1.88)
1.10 (0.93-1.31)
0.70 (0.28-1.72)
0.62 (0.28-1.39)
0.84 (0.70-1.02)

0.99 (0.87-1.13)
Reference
0.99 (0.84-1.17)
0.95 (0.77-1.16)
0.88 (0.69-1.10)
0.91 (0.70-1.18)
0.93 (0.70-1.24)

1.05 (0.93-1.19)
Reference
1.02 (0.87-1.18)
1.05 (0.88-1.26)
0.95 (0.76-1.17)
1.09 (0.86-1.37)
1.10 (0.84-1.43)

0.99 (0.86-1.14)
Reference
1.10 (0.92-1.32)
1.05 (0.85-1.31)
1.04 (0.82-1.32)
0.94 (0.70-1.25)
1.05 (0.78-1.41)

0.88 (0.76-1.01)
Reference
1.00 (0.84-1.19)
1.09 (0.89-1.33)
1.04 (0.83-1.31)
0.80 (0.61-1.06)
0.97 (0.73-1.31)

1.17 (0.97-1.42)
Reference
1.15 (0.91-1.45)
1.12 (0.85-1.48)
1.02 (0.74-1.41)
0.85 (0.57-1.25)
1.13 (0.75-1.69)

1.03 (0.93-1.14)
Reference
0.86 (0.46-1.61)

0.87 (0.79-0.96)b
Reference
1.53 (0.96-2.45)

0.98 (0.88-1.09)
Reference
1.09 (0.59-2.00)

0.91 (0.82-1.02)
Reference
1.55 (0.84-2.85)

0.92 (0.80-1.06)
Reference
1.68 (0.79-3.61)
Continued next page
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TABLE 3. (Continued)

Previous transplant
eGFR at discharge, ml/min per 1.73 m2
≥90
60-89
30-59
≤29
Unknown
Function status at transplant
Severe impairment
Moderate impairment
Mild impairment
Unknown
Donor factors
Donor Risk Index score
0 to <1.5
1.5 to <2.0
2.0 to <2.5
≥2.5
Living donor
Transplant year
2006-2009
2010-2012
2013-2014

Tac + MPA/AZA

Tac alone, Tac + Pred

mTORi-based

CsA-based

Other

1.01 (0.84-1.21)

1.41 (1.21-1.64)a

0.93 (0.76-1.14)

1.50 (1.26-1.79)a

1.42 (1.14-1.77)c

Reference
0.95 (0.83-1.08)
0.97 (0.84-1.12)
1.10 (0.90-1.34)
0.70 (0.56-0.87)b

Reference
0.92 (0.82-1.03)
0.84 (0.74-0.95)b
0.71 (0.59-0.85)a
0.78 (0.65-0.93)b

Reference
1.27 (1.09-1.47)c
1.60 (1.38-1.86)a
2.11 (1.73-2.58)a
1.09 (0.87-1.36)

Reference
1.09 (0.94-1.26)
1.09 (0.94-1.27)
1.03 (0.83-1.27)
0.97 (0.77-1.23)

Reference
1.21 (1.01-1.45)b
1.21 (0.99-1.48)
0.95 (0.71-1.28)
0.83 (0.62-1.12)

1.09 (0.94-1.25)
1.06 (0.93-1.21)
Reference
0.37 (0.24-0.57)a

1.12 (0.98-1.27)
0.97 (0.86-1.09)
Reference
0.79 (0.53-1.17)

1.09 (0.94-1.26)a
1.03 (0.90-1.19)
Reference
0.57 (0.37-0.86)b

1.45 (1.25-1.68)a
1.18 (1.02-1.37)b
Reference
0.79 (0.49-1.28)

1.11 (0.92-1.35)
1.20 (1.00-1.44)b
Reference
0.71 (0.40-1.28)

Reference
0.99 (0.88-1.11)
0.99 (0.86-1.15)
0.86 (0.70-1.05)
0.87 (0.65-1.16)

Reference
0.98 (0.88-1.09)
1.04 (0.92-1.19)
0.99 (0.82-1.18)
1.20 (0.95-1.53)

Reference
0.90 (0.79-1.01)
0.88 (0.75-1.02)
0.79 (0.63-0.99)b
0.63 (0.46-0.88)b

Reference
1.06 (0.93-1.20)
0.97 (0.83-1.14)
0.83 (0.66-1.04)
0.89 (0.66-1.19)

Reference
0.93 (0.79-1.09)
0.85 (0.70-1.05)
0.90 (0.67-1.19)
1.07 (0.74-1.55)

Reference
0.60 (0.51-0.71)a
0.43 (0.36-0.51)a

Reference
0.61 (0.53-0.70)a
0.35 (0.30-0.40)a

Reference
0.71 (0.59-0.85)a
0.67 (0.56-0.81)a

Reference
0.95 (0.80-1.14)
0.52 (0.43-0.63)a

Reference
0.64 (0.52-0.79)a
0.26 (0.21-0.33)a

P values: a P < 0.0001; b 0.02 ≤ P < 0.05; c 0.0001 ≤ P < 0.01;

to 58.5% for steroid-sparing, 0% to 100% for MPA/AZAsparing, 0% to 50.0% for mTORi-based, and 0% to 45.6%
for CsA-based ISx. This variation across centers persisted at
7 to 12 months posttransplant (Figure S2, SDC, http://links.
lww.com/TXD/A104).
Hierarchical logistic regression models demonstrated that
between-center variation in use of specific ISx regimens was
significantly greater than expected based on differences in recipient and donor characteristics (P<0.001) (Figure 2). In the
first 0 to 6 months posttransplant, 35.0% of centers used
steroid-sparing ISx more frequently than expected, 33.9%
used MPA/AZA-sparing more than expected; use of mTORibased and CsA-based ISx was higher than expected at
31.1% and 24.4% of centers, respectively (Table 4A). In
the 7- to 12-month period, centers were more uniform in
ISx patterns, shown as a reduction in the number of centers
with use above or below the reference probability and a
lower degree of heterogeneity (Table 4B; Figure S3, SDC,
http://links.lww.com/TXD/A105).
In the first 6 months posttransplant, unadjusted ICCs suggest that 39% of the variation in steroid-sparing and MPA/
AZA-sparing ISx use was due to “center effect,” whereas
32% and 25% of the variation in mTORi-based and CsAbased ISx, respectively, were driven by center preference
(Table 5A). Similar results were noted after adjustment of
ICC for recipient, donor, and transplant factors. Patient
characteristics explained less than 10% of the variation in use
of all regimens. Median odds ratio from case-factor adjusted
analysis varied from 2.8 to 4.0. Thus, a recipient with a given
set of characteristics was, on average, 4.0 times as likely to
receive a steroid- or antimetabolite-sparing regimen as triple
therapy, at specific centers. Between 6 and 12 months,

FIGURE 1. Proportion of patients receiving each maintenance ISx
option in months 0 to 6 after liver transplant across US centers
(2006-2014). Each horizontal bar represents an individual center
within US regions ordered by the proportion of patients receiving
each regimen.
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FIGURE 2. Empirical Bayes estimates for likelihood of use of each maintenance ISx regimen compared with triple therapy in months 0 to 6 after liver
transplant. The red bar demonstrates the national average rate of use of each regimen (within pairwise regimen comparisons). Each red dot represents
adjusted use at one center, and the blue bars reflect 95% CIs for use at the center determined by EBEs, adjusting for case factors of transplants at the
center; exclusion of the national average by a 95% CI reflects adjusted center use significantly above or below the national average.

unadjusted and adjusted ICCs varied less due to “center
effect” across all ISx (Table 5B).
DISCUSSION
This study provides the first rigorous assessment of variation in long-term ISx regimen selection in liver transplant recipients in a national cohort with a sample size large enough
to distinguish the effects of center practice and clinical case
factors. Our results suggest that liver transplant ISx is far
from uniform nationally, with selection of some regimens
varying from 0% to 100% of recipients across centers. The
degree of variation was higher in the first 6 months than in
months 7 to 12 after transplant, when minimized regimens

were favored. Multivariate analysis confirmed that center
protocol was a stronger determinant of ISx selection than patient or donor characteristics.
Overall, we observed a reduction in the intensity of ISx exposure over time after liver transplant. Tac-based triple ISx
was the most commonly used maintenance regimen in the
first 6 months; however, only 23% of patients remained on
this regimen by months 7 to 12. In contrast, patients started
on reduced ISx regimens were more likely to remain on them.
Only 4.5% patients who initially received MPA/AZA-sparing
regimens and 5.2% who initially received steroid-sparing
regimens were converted to triple therapy during months
7 to 12 after transplant. This pattern may suggest that triple
therapy is not needed after liver transplant in many cases,

TABLE 4.

Center-level EBEs adjusted for case-level characteristicsa
(A) Months 0-6
ISx regimen (reference:
Tac+MPA/AZA+Pred)
Tac+MPA/AZA
Tac alone, TAC+Pred
mTORi-based
CsA-based
Other

No. centers in
pairwise comparison

No. centers significantly
above reference probability

No. centers significantly
below reference probability

120
124
122
123
121

42 (35.0%)
42 (33.9%)
38 (31.1%)
30 (24.4%)
35 (28.9%)

38 (31.7%)
38 (30.6%)
28 (23.0%)
27 (22.0%)
20 (16.5%)

No. of centers in
pairwise comparison

No. of centers significantly
above reference probability

No. of centers significantly
below reference probability

120
123
120
119
118

27 (22.5%)
27 (22.0%)
35 (29.2%)
32 (26.9%)
22 (18.6%)

22 (18.3%)
22 (17.9%)
25 (20.8%)
19 (16.0%)
14 (11.9%)

(B) Months 7-12
ISx regimen (reference:
Tac+MPA/AZA+Pred)
Tac+MPA/AZA
Tac alone, TAC+Pred
mTORi-based
CsA-based
Other
a

Constructed from pairwise comparisons of regimen of interest versus reference regimen of Tac + MPA/Aza + Pred.
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TABLE 5.

Heterogeneity across unadjusted and both adjusted modelsa
(A) Months 0-6
ISx regimen (reference:
Tac+MPA/AZA+Pred)
Tac+MPA/AZA
Tac alone, TAC+Pred
mTORi-based
CsA-based
Other

Proportion of variance in hierarchical
Proportion of variance in hierarchical
Proportion of variance in
model explained by center
MOR
model explained by center,
MOR
model explained by
characteristics (unadjusted)
(unadjusted)
adjusted for case factors
(adjusted)
case factors
0.39
0.39
0.32
0.25
0.26

4.00
3.96
3.25
2.75
2.78

0.39
0.39
0.32
0.25
0.27

4.02
3.95
3.28
2.74
2.85

0.09
0.08
0.06
0.06
0.04

(B) Months 7-12
ISx regimen (reference:
Tac+MPA/AZA+Pred)
Tac+MPA/AZA
Tac alone, TAC+Pred
mTORi-based
CsA-based
Other
a

Proportion of variance in hierarchical
MOR
Proportion of variance in hierarchical
MOR
Proportion of variance in
model explained by center
(unadjusted)
model explained by center,
(adjusted)
model explained by
characteristics (unadjusted)
adjusted for case factors
case factors
0.19
0.24
0.27
0.19
0.14

2.31
2.61
2.87
2.28
2.01

0.23
0.26
0.28
0.21
0.16

2.56
2.76
2.98
2.42
2.10

0.06
0.07
0.10
0.09
0.04

Proportion of variance in hierarchical model is equal to the ICC.

because AR rates are low and more than 90% of AR events
are steroid-responsive.1
The more frequent use of induction ISx in recipients managed with regimens other than triple therapy may also have
contributed to the low conversion rate. In a nonrandomized
single-center trial, a steroid-free regimen and weaning to
single-agent Tac or SRL at 3 months after thymoglobulin induction yielded 1- and 5-year patient and graft survival comparable
to national averages in registry data.15 In a meta-analysis of
liver transplant recipients, AR was significantly less frequent
when any form of T cell–specific antibody induction was used
compared with no induction (relative risk, 0.85; P<0.05).16
The meta-analysis did not mirror typical practice patterns in
the US, however, as included studies were limited to 19 trials
with corticosteroids administered in all and MPA/AZA in
15 of the 19 trials. Thus, further study is needed to compare
the benefits and risks of early triple ISx, lower intensity ISx with
induction, and lower intensity ISx without induction.2,7,16
The national data demonstrate some expected associations
between ISx choice and recipient characteristics. Older recipients,
those with HCC or hepatitis C as cause of liver failure, and those
with renal insufficiency at discharge were less likely to be managed with Tac-based triple therapy. At 7 to 12 months, use
of triple ISx was more likely in retransplant recipients and
in recipients with AR in the first 6 months. In contrast, recipients with newly diagnosed malignancy were nearly 6 times
more likely to receive mTORi-based ISx.
The role of mTORi in the management of liver transplant
recipients with chronic renal insufficiency remains controversial. In a randomized trial of standard dose, Tac versus
mTORi/reduced Tac, eGFR was 8 mL/min per 1.73 m2
higher in the reduced Tac group. Although there was no difference in the composite endpoint of death, graft loss, and
biopsy-proven rejection at 3 years (P = 0.33), there was a numerically increased risk of AR in the reduced-Tac group
(9.2% vs 4.8%, P = 0.07), leading to study termination.7 A
meta-analysis reviewing mTORi and CNI-based ISx found

that patients converted to mTORi from CNIs had significantly better renal function at 1 year after randomization.
Stratifying for conversion within 6 months versus later after
transplant suggested a trend toward more favorable eGFR
with early conversion. In our national data study, 20% of patients were converted from mTORi-based regimens to CNIbased regimens, though only 2% were converted to triple
therapy. Further analysis is needed to define the outcomes
of mTORi-based ISx outside the clinical trial setting, and
to identify subgroups likely versus unlikely to benefit from
the regimen.
Among patients with HCC, we confirmed increased use of
mTORi-based ISx, which resonates with prior single-center
and meta-analytic data suggesting lower HCC recurrence
risk in patients treated with mTORis compared with
CNIs.17,18 The benefit of mTORi-based ISx remains questionable, however, given the results of a large randomized
trial. In the SiLVER study of 525 liver transplant recipients
with HCC, there was no difference in recurrence-free survival
and patient survival with mTORi versus CNI at 5 years.19
However, there was significant benefit in recurrence-free
and overall survival over the first 3 years after transplant in
patients within Milan criteria who were given mTORi.
Furthermore, there was substantial heterogeneity in other
components of the ISx regimen across centers (eg, use of
induction, steroids, and CNIs), which may have affected
the trial findings.
Associations of metabolic risk factors with ISx selection
also warrant consideration. Among patients who underwent
transplant due to nonalcoholic steatohepatitis (NASH), triple
therapy may worsen diabetic control and contribute to endorgan disease.20-24 Development of diabetes after transplant
was 29% higher in NASH recipients in one study, and may
be worsened by Tac and corticosteroids.25 In our study, diabetic patients were initially commonly treated with MPA/
AZA-sparing regimens (34.4%); 21.9% were given monotherapy with Tac. We found no association between ISx
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choice and increased BMI in early regimen choice. However,
at 7 to 12 months, recipients with high BMI were significantly
more likely to receive a steroid-sparing regimen. We also noted
that recipients with severely impaired functional status and
low BMI were more likely to receive CsA-based regimens. This
association may reflect neurotoxicity associated chronic malnutrition, which may worsen under Tac-based regimens,
resulting in early change to a CsA-based ISx.26
The limitations of the current study include its retrospective, nonrandomized design, although this offers benefits
with regard to sample size and national representation across
US transplant centers. We lacked precise information on ISx
exposure as we lacked data on ISx levels. We studied ISx over
the first year posttransplant, and ISx management may
change after the first posttransplant anniversary. The large
sample size and longitudinal follow-up allowed assessment
of changes in clinical characteristics over time (eg, development
of AR and malignancy). However, other clinical conditions that
affect the choice of ISx are not identified in OPTN data or may
occur after the time of transplant, and therefore are not included
in this analysis. For example, recipients with a history of severe
CNI neurotoxicity, CNI-induced thrombotic microangiopathy,
or nephrotoxicity may be more likely to receive mTORi-based
therapy. Recipients receiving ISx through trials rather than
pharmacy fills cannot be identified through our study data,
although some recipients in the “other” category were likely
managed under study protocols. Finally, the years of data
collection in our study ended in 2014, and ongoing research
is needed to evaluate use of and trends in recently approved
agents, such as everolimus.27
In conclusion, we found that selection of ISx regimen after
liver transplant varies widely across US transplant centers
and largely reflects center choice rather than patient or donor
characteristics, similar to kidney transplant data we previously published.13,28 Whether tailoring ISx therapy to case
factors or using standardized protocols for all patients affects
posttransplant mortality remains to be defined. The current
observation of center-based practice variation frames a natural experiment for future studies to assess the effects of ISx
personalization on patient outcomes and costs with sufficient
power to identify low-probability events.
ACKNOWLEDGMENTS
This work was conducted under the auspices of the
Minneapolis Medical Research Foundation (MMRF), contractor for the Scientific Registry of Transplant Recipients (SRTR),
as a deliverable under contract no. HHSH250201000018C
(US Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems
Bureau, Division of Transplantation). As a US Governmentsponsored work, there are no restrictions on its use. The interpretation and reporting of these data are the responsibility of
the author(s) and in no way should be seen as an official policy of or interpretation by the SRTR or the US Government.
The authors thank SRTR colleague Nan Booth, MSW, MPH,
ELS, for article editing.
REFERENCES
1. Dhanasekaran R. Management of immunosuppression in liver transplantation. Clin Liver Dis. 2017;21:337–353.
2. Rodriguez-Peralvarez M, Guerrero-Misas M, Thorburn D, et al. Maintenance immunosuppression for adults undergoing liver transplantation: a

www.transplantationdirect.com

3.

4.

5.
6.

7.

8.
9.
10.

11.
12.
13.

14.

15.

16.

17.
18.

19.

20.

21.

22.

23.
24.

25.

26.

27.
28.

network meta-analysis. Cochrane Database Syst Rev. 2017;
3:CD011639.
Muduma G, Saunders R, Odeyemi I, et al. Systematic review and metaanalysis of tacrolimus versus ciclosporin as primary immunosuppression
after liver transplant. PLoS One. 2016;11:e0160421.
Wimmer CD, Angele MK, Schwarz B, et al. Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation:
a single center experience with 609 patients. Transpl Int. 2013;26:999–1006.
Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of
a nonrenal organ. New Engl J Med. 2003;349:931–940.
Saliba F, Duvoux C, Gugenheim J, et al. Efficacy and safety of everolimus and
mycophenolic acid with early tacrolimus withdrawal after liver transplantation: a
multicenter randomized trial. Am J Transplant. 2017;17:1843–1852.
Glover TE, Watson CJ, Gibbs P, et al. Conversion from calcineurin to mammalian target of rapamycin inhibitors in liver transplantation: a meta-analysis
of randomized controlled trials. Transplantation. 2016;100:621–629.
Ventura-Aguiar P, Campistol JM, Diekmann F. Safety of mTOR inhibitors in
adult solid organ transplantation. Expert Opin Drug Saf. 2016;15:303–319.
Massoud O, Wiesner RH. The use of sirolimus should be restricted in liver
transplantation. J Hepatol. 2012;56:288–290.
Khorsandi SE, Heaton N. Optimization of immunosuppressive medication
upon liver transplantation against HCC recurrence. Transl Gastroenterol
Hepatol. 2016;1:25.
de Fijter JW. Cancer and mTOR inhibitors in transplant recipients. Transplantation. 2017;101:45–55.
Kim WR, Lake JR, Smith JM, et al. OPTN/SRTR 2016 annual data report:
liver. Am J Transplant. 2018;18(Suppl 1):172–253.
Axelrod DA, Naik AS, Schnitzler MA, et al. National variation in use of immunosuppression for kidney transplantation: a call for evidence-based
regimen selection. Am J Transplant. 2016;16:2453–2462.
Merlo J, Chaix B, Ohlsson H, et al. A brief conceptual tutorial of multilevel
analysis in social epidemiology: using measures of clustering in multilevel
logistic regression to investigate contextual phenomena. J Epidemiol
Community Health. 2006;60:290–297.
Yoo MC, Vanatta JM, Modanlou KA, et al. Steroid-free liver transplantation
using rabbit antithymocyte globulin induction in 500 consecutive patients.
Transplantation. 2015;99:1231–1235.
Penninga L, Wettergren A, Wilson CH, et al. Antibody induction versus
placebo, no induction, or another type of antibody induction for liver transplant recipients. Cochrane Database Syst Rev. 2014:CD010253.
Klintmalm GB, Nashan B. The role of mTOR inhibitors in liver transplantation: reviewing the evidence. J Transplant. 2014;2014:845438.
Lerut J, Iesari S, Foguenne M, et al. Hepatocellular cancer and recurrence
after liver transplantation: what about the impact of immunosuppression?
Transl Gastroenterol Hepatol. 2017;2:80.
Geissler EK, Schnitzbauer AA, Zulke C, et al. Use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, openlabel phase 3 trial. Transplantation. 2016;100:116–125.
Goldberg D, Ditah IC, Saeian K, et al. Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver
transplantation. Gastroenterology. 2017;152:1090–1099.e1.
Flemming JA, Kim WR, Brosgart CL, et al. Reduction in liver transplant
wait-listing in the era of direct-acting antiviral therapy. Hepatology. 2017;
65:804–812.
Salameh H, Raff E, Erwin A, et al. PNPLA3 gene polymorphism is associated with predisposition to and severity of alcoholic liver disease. Am J
Gastroenterol. 2015;110:846–856.
Germani G, Becchetti C. Liver transplantation for non-alcoholic fatty liver
disease. Minerva Gastroenterol Dietol. 2018;64:138–146.
Malhi H, Allen AM, Watt KD. Nonalcoholic fatty liver: optimizing
pretransplant selection and posttransplant care to maximize survival. Curr
Opin Organ Transplant. 2016;21:99–106.
Stepanova M, Henry L, Garg R, et al. Risk of de novo post-transplant type
2 diabetes in patients undergoing liver transplant for non-alcoholic
steatohepatitis. BMC Gastroenterol. 2015;15:175.
Souto-Rodriguez R, Molina-Perez E, Castroagudin JF, et al. Differences in
the incidence and clinical evolution of early neurotoxicity after liver transplantation based on tacrolimus formulation used in the immunosuppressive induction protocol. Transplant Proc. 2014;46:3117–3120.
Yee ML, Tan HH. Use of everolimus in liver transplantation. World J
Hepatol. 2017;9:990–1000.
Dharnidharka VR, Naik AS, Axelrod DA, et al. Center practice drives variation in choice of US kidney transplant induction therapy: a retrospective
analysis of contemporary practice. Transpl Int. 2018;31:198–211.

